A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated

University of Iowa41 enrolled

Overview

* CpG has the potential to stimulate the immune system * this study will evaluate the safety of CpG given sub-q or IV * purpose is to measure biological changes in CLL cells after receiving CpG

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Chronic Lymphocytic Leukemia

Interventions

CpG 7909DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of CLL * CLL previously treated * Hemoglobin \>/= 10 * Platelets \>/= 50,000 * Neutrophils \>= 1,000 - Exclusion Criteria: * patients with brain mets * patients with autoimmune disease * patients on corticosteroids or immunosuppressants * patients with uncontrolled intercurrent illness * pregnant women * HIV patients receiving combination anti-retroviral therapy

Locations (2)

University of Iowa

Iowa City, Iowa, United States

Mayo Clinic

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

maximum tolerated dose

Time frame: at study completion

Secondary Outcomes

response

Time frame: at end of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.